$VTAK Catheter Precision, Inc. (NYSE American: VTA
Post# of 91
(Total Views: 117)
Posted On: 12/20/2023 1:25:03 PM
$VTAK Catheter Precision, Inc. (NYSE American: VTAK) Releases Q2 2023 Financials and Corporate Highlights
https://www.benzinga.com/pressreleases/23/12/...highlights
Catheter Precision, Inc.
VTAK
released its financials and highlights for the Second Quarter of 2023, unveiling total assets amounting to $35.5 million and cash reserves of $7.4 million and revenues for the six-month period ending on June 30, 2023. Catheter Precision, Inc., is a U.S.-based medical device company, offering innovative solutions to enhance the treatment of cardiac arrhythmias. The company collaborates with physicians to develop cutting-edge technology for electrophysiology procedures, and it consistently focuses on enhancing its product offerings.
Moreover, in the second quarter, Catheter Precision, Inc. initiated the inaugural LockeT study with the participation of 100 patients. This observational investigation aimed to demonstrate the viability of a cost-effective alternative to current closure methods. (LockeT serves as a suture retention device designed for wound healing. It distributes suture tension across a larger area in conjunction with a figure-of-eight suture closure, temporarily securing sutures).
Additionally, another noteworthy achievement includes the successful enrolment of 125 patients in the VIVO™ patient registry. Follow-up data for these registered patients is anticipated to be disclosed in mid-2024. (VIVO™, or View into Ventricular Onset, is a non-invasive 3D imaging system that empowers physicians to identify the origin of arrhythmias before procedures, thereby streamlining workflow and reducing procedure time). A major milestone in the second quarter involved Catheter Precision's ongoing endeavours to establish crucial VIVO™ accounts in both Europe and the United States. The observational study, emphasizing a competitively priced alternative to prevalent closure methods, underscored the company's dedication to innovation and advancement.
Furthermore, the company has effectively trained and assembled a sales team based in the United States. Another noteworthy development includes the successful onboarding and training of additional personnel in the United States, coupled with the enlistment of a consulting group to secure international contracts for the distribution of the LockeT product. Catheter Precision, Inc. remains dedicated to pursuing intellectual property filings for both LockeT and VIVO™.
https://www.benzinga.com/pressreleases/23/12/...highlights
Catheter Precision, Inc.
VTAK
released its financials and highlights for the Second Quarter of 2023, unveiling total assets amounting to $35.5 million and cash reserves of $7.4 million and revenues for the six-month period ending on June 30, 2023. Catheter Precision, Inc., is a U.S.-based medical device company, offering innovative solutions to enhance the treatment of cardiac arrhythmias. The company collaborates with physicians to develop cutting-edge technology for electrophysiology procedures, and it consistently focuses on enhancing its product offerings.
Moreover, in the second quarter, Catheter Precision, Inc. initiated the inaugural LockeT study with the participation of 100 patients. This observational investigation aimed to demonstrate the viability of a cost-effective alternative to current closure methods. (LockeT serves as a suture retention device designed for wound healing. It distributes suture tension across a larger area in conjunction with a figure-of-eight suture closure, temporarily securing sutures).
Additionally, another noteworthy achievement includes the successful enrolment of 125 patients in the VIVO™ patient registry. Follow-up data for these registered patients is anticipated to be disclosed in mid-2024. (VIVO™, or View into Ventricular Onset, is a non-invasive 3D imaging system that empowers physicians to identify the origin of arrhythmias before procedures, thereby streamlining workflow and reducing procedure time). A major milestone in the second quarter involved Catheter Precision's ongoing endeavours to establish crucial VIVO™ accounts in both Europe and the United States. The observational study, emphasizing a competitively priced alternative to prevalent closure methods, underscored the company's dedication to innovation and advancement.
Furthermore, the company has effectively trained and assembled a sales team based in the United States. Another noteworthy development includes the successful onboarding and training of additional personnel in the United States, coupled with the enlistment of a consulting group to secure international contracts for the distribution of the LockeT product. Catheter Precision, Inc. remains dedicated to pursuing intellectual property filings for both LockeT and VIVO™.
(0)
(0)Ra Medical Systems Inc. (RMED) Stock Research Links
Scroll down for more posts ▼